Skip to main content
Premium Trial:

Request an Annual Quote

Cerner, Claritas Collaborate on Personalized Medicine Initiative

NEW YORK (GenomeWeb News) – Cerner and Claritas Genomics said today that they will partner on a personalized medicine initiative to better integrate next-generation sequencing-based diagnostics into healthcare.

Claritas will use Cerner's Millenium Helix solution — a laboratory information system designed specifically for molecular data and genetic information — and will join Cerner's Reference Lab Network so that other Reference Lab Network partners can order and obtain results from Claritas.

Claritas, a spinout of Boston Children's Hospital that was formed in February 2013, offers genetic tests for pediatric diseases, offers exome sequencing on Life Technologies' Ion Proton system, and is developing additional tests on the Proton.

Also as part of the agreement, Cerner's wholly owned subsidiary Cerner Capital has invested in Claritas, becoming a minority shareholder, and bringing Claritas' Series A financing round to a close. In addition, Clay Patterson, managing director of Cerner Capital, has joined the Claritas board of directors.

"Cerner has long focused on the power of genomics and its impact to clinical processes, and this relationship will help advance the field and define a meaningful narrative in personalized medicine between the realms of research, diagnostics, and clinical practice," Dick Flanigan, senior vice president of Cerner, said in a statement.

"One of Claritas' goals is to enable providers at any pediatric center or practice to use genomics in routine medical care," Claritas CEO Patrice Milos said in the statement. "As a leading provider of both laboratory management systems and EMR systems in the world, Cerner has decades of experience synthesizing complex medical information across organizations to inform patient care and we are extremely pleased to have them as a strategic partner."

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.